BioCentury
ARTICLE | Company News

PrognosDx, University of California deal

June 22, 2009 7:00 AM UTC

PrognosDx received exclusive, worldwide rights to the university's IP covering histone modification technology. PrognosDx is developing laboratory products for cancer and other diseases based on histo...